Alterity Therapeutics Limited

NasdaqCM:ATHE Rapporto sulle azioni

Cap. di mercato: US$10.5m

Alterity Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Alterity Therapeutics's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 9% per year.

Informazioni chiave

-2.6%

Tasso di crescita degli utili

31.6%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.0%
Tasso di crescita dei ricavi9.0%
Rendimento del capitale proprio-138.6%
Margine netto-475.8%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

Ripartizione dei ricavi e delle spese

Come Alterity Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqCM:ATHE Ricavi, spese e utili (AUD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 244-19519
31 Mar 244-16515
31 Dec 233-12412
30 Sep 234-13512
30 Jun 234-14513
31 Mar 235-14514
31 Dec 225-14516
30 Sep 225-14515
30 Jun 225-13615
31 Mar 225-13514
31 Dec 215-13713
30 Sep 215-14813
30 Jun 214-15712
31 Mar 212-16711
31 Dec 200-16510
30 Sep 200-15410
30 Jun 200-13310
31 Mar 202-13411
31 Dec 194-13413
30 Sep 195-12413
30 Jun 195-12413
31 Mar 195-11412
31 Dec 184-10410
30 Sep 184-948
30 Jun 183-847
31 Mar 183-845
31 Dec 173-844
30 Sep 173-845
30 Jun 173-846
31 Mar 174-847
31 Dec 164-948
30 Sep 164-849
30 Jun 165-8410
31 Mar 165-8411
31 Dec 156-7512
30 Sep 156-7512
30 Jun 156-6512
31 Mar 158-6613
31 Dec 1410-7313
30 Sep 149-10314
30 Jun 148-13515
31 Mar 146-12313
31 Dec 134-11311

Guadagni di qualità: ATHE is currently unprofitable.

Margine di profitto in crescita: ATHE is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: ATHE is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.

Accelerare la crescita: Unable to compare ATHE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: ATHE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendimento del capitale proprio

ROE elevato: ATHE has a negative Return on Equity (-138.6%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate